Latest PRPO news and sentiment

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

This article compares two specialty cancer diagnostics companies, Precipio, Inc. (PRPO) and Biodesix, Inc. (BDSX), to determine which stock is a better investment. While both operate in cancer diagnostics, they have different business focuses and financial profiles. The analysis concludes that PRPO is the better buy due to its attractive valuation, expanding product commercialization, integrated pathology-product model, and improving financial sustainability.

Precipio (PRPO) Financial Update: Available Data Shows the Latest Reported Performance under the Current Snapshot

PRPO | Precipio, Inc. Common Stock Financials - Revenue Breakdown

Precipio reports Q2 results

* Precipio press release [https://seekingalpha.com/pr/20620078-precipio-announces-q2minus-2026-financial-results] (PRPO [https://seekingalpha.com/symbol/PRPO]): Q2 Revenue of $7M (+22.8% Y/Y). * Adjusted EBITDA – $0.4M vs. $(0.2)M in Q1-2026. * Cash flow - Cash Flow generated from operations was $0.7M in Q2-2026; total increase in cash was $0.5 million, resulting in an end of quarter cash balance exceeding $3M, vs $1.1M in Q2-2025. MORE ON PRECIPIO * Historical earnings data for Precipio [https://seekingalpha.com/symbol/PRPO/earnings] * Financial information for Precipio [https://seekingalpha.

Precipio, Inc. Q2 2026 Earnings Call Summary

(PRPO) Risk Channels and Responsive Allocation

This article analyzes Precipio Inc. (NASDAQ: PRPO), identifying a weak near-term sentiment despite potential long-term strength. It highlights an exceptional 71.3:1 risk-reward setup targeting a 19.1% gain with only 0.3% risk. The analysis provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis.

Precipio, Inc. 2026: Revenue $7.02M, EPS ($0.12) — 10-Q Summary

Precipio, Inc. (PRPO) reported its second-quarter 2026 results, showing a revenue increase to $7.02 million from $5.63 million in the prior year, a 24.7% rise. Despite the revenue growth, the company recorded a net loss of ($219K) and a diluted loss per share of ($0.12), compared to a net income of $74K and EPS of $0.05 in the previous year. The growth was driven by higher case volumes and increased product sales, mainly from pathology service volume, although the average price per case declined due to a shift towards lower-priced products.

Precipio Inc (PRPO) Stock News Today

This article provides current stock news for Precipio Inc (PRPO). As of the article's publication, PRPO's stock is trading at $23.970, up +2.17%, with a market cap of 42.75M USD. The article notes that more news is expected soon regarding the company.

(PRPO) Movement as an Input in Quant Signal Sets

This article analyzes Precipio Inc. (NASDAQ: PRPO) using AI models to generate trading strategies across different risk profiles. Key findings indicate divergent sentiment, suggesting choppy conditions, and highlights support and resistance levels. The analysis provides specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging strategies.

Precipio Schedules Q2 2026 Shareholder Update Call

Precipio (PRPO) announced it will host its Q2 2026 shareholder update call on August 17, 2026, at 5:00 p.m. ET to discuss performance in its cancer diagnostics businesses. CEO Ilan Danieli will provide remarks on progress and engage in a live Q&A session. TipRanks' AI Analyst, Spark, rates PRPO as Neutral, citing improving financials but noting negative net income and mixed technical positioning.